| Literature DB >> 34267668 |
Shiqiang Hou1,2, Dandan Chen1,2, Jie Liu3, Shasha Chen1,2, Xiaochun Zhang1,2, Yuan Zhang1,2, Mingfei Li1,2, Wenzhi Pan1,2, Daxin Zhou1,2, Lihua Guan1,2, Junbo Ge1,2.
Abstract
Pulmonary arterial hypertension (PAH) is an immune-mediated disease with poor prognosis and associated with various inflammatory immune diseases. In fact, its pathogenesis is far from clear. Although long non-coding RNAs (lncRNAs) have been implicated in PAH, the molecular mechanisms remain largely unknown. For the first time, in lungs of monocrotaline-induced PAH rat models, we simultaneously detected the expression profiles of lncRNAs and mRNAs by high-throughput sequencing, and explored their roles with bioinformatics analysis and cell assay to discover more potential pathogenesis about PAH. Our data identified that a total of 559 lncRNAs and 691 mRNAs were differentially expressed in lungs during the pathogenesis of PAH. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses demonstrated that these dysregulated lncRNAs and mRNAs participated in important biological processes and pathways of PAH, among which inflammatory and immune responses represented the chief enriched pathway. The lncRNA-mRNA co-expression network was developed to uncover the hidden interactions between lncRNAs and mRNAs. Further, the expression levels of lncRNAs (NONRATT018084.2, NONRATT009275.2, NONRATT007865.2, and NONRATT026300.2) and mRNAs (LGALS3, PDGFC, SERPINA1, and NFIL3) were confirmed using quantitative real-time PCR. In the end, lncRNA NONRATT009275.2 could facilitate macrophage polarization to M2 type and be involved in inflammatory immune response. In conclusion, this study provided candidate drug targets and potential roles on lncRNAs in the pathogenesis of PAH, and several key regulatory genes were identified, which laid the initial foundation for further mechanism study in PAH.Entities:
Keywords: inflammatory immune disease; long non-coding RNA; lung; messenger RNA; pulmonary arterial hypertension
Year: 2021 PMID: 34267668 PMCID: PMC8277419 DOI: 10.3389/fphar.2021.709816
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
FIGURE 1Profiling of lncRNAs and mRNAs between PAH group and control group. (A,B) Heat maps showed the hierarchical clustering of differential expression in lncRNAs and mRNAs between PAH group (PAH) and control group (Ctrl). (C,D) MA plots showed the differential expression of lncRNAs and mRNAs between two groups. Differential expression was indicated as “red”. (E,F) Volcano plots were depicted to visualize the up-regulated and down-regulated lncRNAs and mRNAs between two groups. Up-regulated expression was indicated as “red”, and down-regulated expression was indicated as “green”.
Top 10 significantly differential expressed lncRNAs identified by high-throughput sequencing.
| Up-regulated | Down-regulated | ||||
|---|---|---|---|---|---|
| lncRNAs |
| Fold change | lncRNAs |
| Fold change |
| NONRATT033431.1 | 0.000 | 141.460 | NONRATT002354.2 | 0.002 | 0.001 |
| NONRATT011934.2 | 0.000 | 134.949 | NONRATT013281.2 | 0.001 | 0.004 |
| NONRATT017032.2 | 0.000 | 121.137 | NONRATT006789.2 | 0.003 | 0.005 |
| NONRATT023671.2 | 0.001 | 116.557 | NONRATT016013.2 | 0.002 | 0.006 |
| NONRATT019381.2 | 0.001 | 92.126 | NONRATT030453.2 | 0.000 | 0.011 |
| NONRATT033423.1 | 0.000 | 78.938 | NONRATT024649.2 | 0.015 | 0.017 |
| NONRATT016587.2 | 0.039 | 77.800 | NONRATT011637.2 | 0.020 | 0.017 |
| NONRATT015297.2 | 0.004 | 74.805 | NONRATT012347.2 | 0.003 | 0.017 |
| NONRATT033430.1 | 0.000 | 68.169 | NONRATT022660.2 | 0.000 | 0.018 |
| NONRATT025409.2 | 0.000 | 66.438 | NONRATT004729.2 | 0.013 | 0.021 |
Top 10 significantly differential expressed mRNAs identified by high-throughput sequencing.
| Up-regulated | Down-regulated | ||||
|---|---|---|---|---|---|
| mRNAs |
| Fold change | mRNAs |
| Fold change |
| RT1-S2 | 0.001 | 116.382 | Ttc23 | 0.004 | 0.007 |
| Ighg | 0.000 | 93.277 | Atp1b1 | 0.000 | 0.008 |
| RGD1563231 | 0.000 | 81.799 | Fosb | 0.013 | 0.011 |
| AABR07065699.3 | 0.000 | 75.646 | LOC100911581 | 0.005 | 0.013 |
| Zbtb44 | 0.045 | 65.602 | Synj1 | 0.004 | 0.016 |
| Ighm | 0.000 | 60.140 | Emr4 | 0.009 | 0.019 |
| LOC100360581 | 0.039 | 77.800 | Fam8a1 | 0.000 | 0.022 |
| Hspbap1 | 0.007 | 57.390 | Atf3 | 0.008 | 0.024 |
| Sult1c2a | 0.036 | 54.683 | Fos | 0.010 | 0.026 |
| RGD1565617 | 0.000 | 48.433 | Sugt1 | 0.033 | 0.043 |
FIGURE 2GO enrichment and KEGG pathway analyses for the total dysregulated mRNAs. Top 10 enriched GO terms of total dysregulated mRNAs were presented according to (A) biological process, (B) cellular component and (C) molecular function, respectively. (D) KEGG pathway analysis of the total dysregulated mRNAs in PAH.
FIGURE 3The lncRNA-mRNA Co-Expression Network. The red triangle nodes represented differentially expressed lncRNAs, and the green oval nodes represented differentially expressed mRNAs. The edges showed the interactions between lncRNAs and mRNAs.
FIGURE 4Verification of the critical dysregulated lncRNAs and mRNAs by qRT-PCR. (A–D) The expression levels of four lncRNAs (NONRATT018084.2, NONRATT009275.2, NONRATT007865.2 and NONRATT026300.2). (E–H) The expression levels of four mRNAs (LGALS3, PDGFC, SERPINA1, and NFIL3). GAPDH was used as the internal control. The data are expressed as the mean ± SD (n = 3). **p < 0.01 vs. the control group.
FIGURE 5LncRNA NONRATT009275.2 facilitated macrophage polarization to M2 type. (A) The expression level of NONRATT009275.2 in transfected BMDMs. (B) The macrophage polarization was detected by flow cytometry. (C) The F4/80 and CD206 positive cells were quantified. (D,E) The Arg-1 and PDGFC mRNA expression were tested by qRT-PCR. GAPDH was used as the internal control. The data are expressed as the mean ± SD (n = 3). **p < 0.01 vs. the IL-4 + vector group.